Robert (Bob) Moses was formerly Corporate Vice President of CSL Limited. Mr. Moses draws on more than 40 years’ experience in the pharmaceutical/biotechnology industry. During the period 1993-2001, Mr. Moses played a central role in CSL’s development internationally. Prior to joining CSL, Mr. Moses was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company, and Corporate Manager of New Business Development at ICI (now Orica). Mr. Moses is also the former Non-Executive Chairman of TGR Biosciences Pty Ltd. Mr. Moses also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly.
Mark Diamond has over 20 years’ experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics Limited as MD and CEO in 2001, Mr. Diamond was employed in the US as Director, Project Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding’s European operation based in the UK and International Business Development Manager with Faulding in Australia.
Dr Graham Mitchell
Graham Mitchell is an advisor in Innovation to the Victorian, Tasmanian and Northern Territory Governments. Dr. Mitchell through Foursight Associates Pty Ltd, acts as joint Chief Scientist for Victorian Government Departments. Prof. Mitchell is a Non-Executive Director of Compumedics Limited, Avipep Pty Ltd, Adelaide Research and Innovation Pty Ltd and is a principal of Foursight. Dr. Mitchell has held the position of Director of Research in the R&D Division of CSL Limited, Non-Executive director of the Geoffrey Gardiner Dairy Foundation and for many years was a research scientist at The Walter & Eliza Hall Institute.
Mr William Goolsbee
Mr. Goolsbee was founder, Chairman and Chief Executive Officer of Horizon Medical Inc. from 1987 until its acquisition by a unit of UBS Private Equity in 2002. Mr. Goolsbee was a founding Director of ImmunoTherapy Corporation in 1993, and became Chairman in 1995, a position he held until overseeing the successful acquisition of ImmunoTherapy by AVI Biopharma, Inc. (now Sarepta Therapeutics) in 1998. Mr. Goolsbee served as Chairman of privately held BMG Pharma LLC, a pharmaceutical company, from 2006 through 2011 and of Metrodora Therapeutics until 2015.
Mr. Goolsbee holds a B.A. degree from the University of California at Santa Barbara.
Dr Gary Pace
Dr Pace is currently a Director of three other public companies; ResMed (ASX/NYSE, RMD); Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) and Transition Therapeutics Inc. (NASDAQ: TTHI), as well as several private companies. He has also previously held directorships in other ASX listed biotechnology companies including Peplin Ltd.
Dr Pace holds a B.Sc. (Hons I) from the University of New South Wales and a PhD from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. He has authored or co-authored over 50 research and review papers, has been awarded 24 patents. In addition he has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland. Dr Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering.